^
Association details:
Biomarker:No biomarker
Cancer:Lung Adenocarcinoma
Drug:Imfinzi (durvalumab) (PD-L1 inhibitor) +
Imjudo (tremelimumab) (CTLA4 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
The following regimens recommended added as Other Recommended for adenocarcinoma, large cell, NSCLC NOS….Tremelimumab-actl + durvalumab + carboplatin + albumin-bound paclitaxel...Tremelimumab-actl + durvalumab + (carboplatin or cisplatin) + pemetrexed
Secondary therapy:
carboplatin + pemetrexed; cisplatin + pemetrexed; carboplatin + albumin-bound paclitaxel